$NURO
NeuroMetrix, Inc. Stock $nuro

$nuro Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000114420414024572 Filed on April 24, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q1
Revenue	$1.344M	$1.332M	$1.400M
YoY Change	15.8%	-4.89%	-32.74%
Cost Of Revenue	$655.3K	$615.1K	$569.8K
YoY Change	30.76%	7.95%	-49.8%
Gross Profit	$688.4K	$716.5K	$831.7K
YoY Change	4.42%	-13.85%	-12.14%
Gross Profit Margin	51.23%	53.81%	59.41%
Selling, General & Admin	$1.843M	$1.593M	$2.013M
YoY Change	-1.57%	-20.88%	-26.12%
% of Gross Profit	267.7%	222.34%	242.1%
Research & Development	$1.465M	$863.7K	$1.073M
YoY Change	60.29%	-19.54%	9.75%
% of Gross Profit	212.78%	120.55%	129.07%
Depreciation & Amortization	$40.00K	$30.00K	$40.00K
YoY Change	0.0%	-25.0%	-42.86%
% of Gross Profit	5.81%	4.19%	4.81%
Operating Expenses	$3.308M	$2.457M	$3.087M
YoY Change	18.72%	-20.41%	-16.64%
Operating Profit	-$2.619M	-$1.740M	-$2.255M
YoY Change	23.15%	-22.83%	-18.19%
Interest Expense	$480.0K	$520.0K	$0.00
YoY Change	-58.62%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.170M	-$1.220M	-$2.250M
YoY Change	60.74%	-45.78%	-18.18%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.171M	-$1.225M	-$2.253M
YoY Change	61.29%	-45.66%	-18.13%
Net Earnings / Revenue	-161.54%	-91.97%	-160.96%
Basic Earnings Per Share
Diluted Earnings Per Share	-$72.33M	-$61.00M	-$225.0M
COMMON SHARES
Basic Shares Outstanding	5.946M shares	5.946M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.69M	$7.580M	$6.890M
YoY Change	42.75%	10.01%	-54.7%
Cash & Equivalents	$13.69M	$7.584M	$6.886M
Short-Term Investments
Other Short-Term Assets	$350.0K	$480.0K	$420.0K
YoY Change	9.38%	14.29%	16.67%
Inventory	$600.0K	$665.7K	$790.0K
Prepaid Expenses
Receivables	$530.0K	$530.7K	$530.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$15.18M	$9.256M	$8.630M
YoY Change	35.35%	7.26%	-51.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$180.4K	$198.5K	$260.0K
YoY Change	-21.75%	-23.67%	-40.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$181.7K	$199.3K	$260.0K
YoY Change	-22.24%	-23.33%	-61.59%
TOTAL ASSETS
Total Short-Term Assets	$15.18M	$9.256M	$8.630M
Total Long-Term Assets	$181.7K	$199.3K	$260.0K
Total Assets	$15.36M	$9.456M	$8.890M
YoY Change	34.18%	6.36%	-51.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$534.5K	$578.0K	$230.0K
YoY Change	154.54%	151.3%	-42.47%
Accrued Expenses	$977.2K	$791.6K	$1.580M
YoY Change	-7.91%	-49.9%	68.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$10.00K
YoY Change			-50.0%
Total Short-Term Liabilities	$2.370M	$1.970M	$1.940M
YoY Change	12.23%	1.54%	-17.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$5.380M	$1.440M	$60.00K
YoY Change	85.52%	2300.0%	-40.0%
Total Long-Term Liabilities	$5.380M	$1.440M	$60.00K
YoY Change	85.52%	2300.0%	-45.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.370M	$1.970M	$1.940M
Total Long-Term Liabilities	$5.380M	$1.440M	$60.00K
Total Liabilities	$7.750M	$3.409M	$2.000M
YoY Change	54.75%	70.44%	-18.73%
SHAREHOLDERS EQUITY
Retained Earnings		-$147.8M
YoY Change
Common Stock		$595.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.610M	$6.047M	$6.900M
YoY Change
Total Liabilities & Shareholders Equity	$15.36M	$9.456M	$8.890M
YoY Change	34.16%	6.36%	-51.5%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$2.171M	-$1.225M	-$2.253M
YoY Change	61.29%	-45.66%	-18.13%
Depreciation, Depletion And Amortization	$40.00K	$30.00K	$40.00K
YoY Change	0.0%	-25.0%	-42.86%
Cash From Operating Activities	-$1.830M	-$1.608M	-$1.802M
YoY Change	-1.61%	-10.76%	-30.31%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$4.115K	$6.064K
YoY Change	100.0%	-32.14%	-75.16%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$20.00K	-$4.115K	-$6.064K
YoY Change	100.0%	-32.14%	-75.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.960M	$0.00	-$5.281K
YoY Change	73.8%	-100.0%	-100.07%
NET CHANGE
Cash From Operating Activities	-1.830M	-$1.608M	-$1.802M
Cash From Investing Activities	-20.00K	-$4.115K	-$6.064K
Cash From Financing Activities	7.960M	$0.00	-$5.281K
Net Change In Cash	6.110M	-$1.612M	-$1.813M
YoY Change	125.46%	-11.09%	-136.84%
FREE CASH FLOW
Cash From Operating Activities	-$1.830M	-$1.608M	-$1.802M
Capital Expenditures	-$20.00K	$4.115K	$6.064K
Free Cash Flow	-$1.810M	-$1.612M	-$1.808M
YoY Change	-2.16%	-10.83%	-30.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	863718	USD
CY2014Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	446216	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1146757	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	2456691	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1740235	USD
CY2014Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1036	USD
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-514600	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1224599	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	716456	USD
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5931134	shares
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1647908	USD
CY2014Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14963	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15277	USD
CY2014Q1	nuro	Common Stock Warrants CommonStockWarrants	1424003	USD
CY2013Q4	nuro	Common Stock Warrants CommonStockWarrants	1938603	USD
CY2014Q1	us-gaap	Liabilities Liabilities	3408778	USD
CY2013Q4	us-gaap	Liabilities Liabilities	3601788	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	595	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	595	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	153882944	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	153806460	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147836679	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146612080	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7583538	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9195753	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	530666	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	390922	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	665695	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	563036	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	476407	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	416816	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	9256306	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	10566527	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	198463	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	229313	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	869	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	923	USD
CY2014Q1	us-gaap	Assets Assets	9455638	USD
CY2013Q4	us-gaap	Assets Assets	10796763	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	577986	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	322896	USD
CY2014Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	536693	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	386004	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	791641	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	870196	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	63492	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	68812	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1969812	USD
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	867427	shares
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2168168	shares
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	6046860	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	7194975	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9455638	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10796763	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q1	us-gaap	Cost Of Revenue CostOfRevenue	569784	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	831670	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5945581	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5945581	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5945581	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5945581	shares
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1073419	USD
CY2013Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	779841	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1233594	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	3086854	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2255184	USD
CY2013Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1769	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-2253415	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2131745	shares
CY2014Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	285218	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	205320	USD
CY2014Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	380477	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	357716	USD
CY2014Q1	nuro	Technology Fees TechnologyFees	450000	USD
CY2013Q4	nuro	Technology Fees TechnologyFees	450000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	178847	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	263642	USD
CY2014Q1	nuro	Clinical Study Obligations ClinicalStudyObligations	28425	USD
CY2013Q4	nuro	Clinical Study Obligations ClinicalStudyObligations	51424	USD
CY2014Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	32167	USD
CY2013Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	32688	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102202	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	72442	USD
CY2013Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2015-03-31
CY2014Q1	us-gaap	Share Price SharePrice	2.34
CY2013Q4	us-gaap	Share Price SharePrice	2.92
CY2014Q1	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	2.00
CY2013Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	2.00
CY2013	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0171	pure
CY2014Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0173	pure
CY2013	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P4Y5M
CY2014Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P4Y2M
CY2013	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.6760	pure
CY2014Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.6930	pure
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2400000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2425732	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3926600	USD
CY2014Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	2425732	USD
CY2013Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	3926600	USD
CY2014Q1	nuro	Common Stock Warrants Fair Value Disclosure CommonStockWarrantsFairValueDisclosure	1424003	USD
CY2013Q4	nuro	Common Stock Warrants Fair Value Disclosure CommonStockWarrantsFairValueDisclosure	1938603	USD
CY2014Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	1424003	USD
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	1938603	USD
CY2014Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	2500000	USD
CY2014Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2015-01-15
CY2014Q1	nuro	Restricted Cash Collateral Letters Of Credit RestrictedCashCollateralLettersOfCredit	225000	USD
CY2014Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	2275000	USD
CY2014Q1	nuro	Line Of Credit Facility Maximum Borrowing Capacity In Case Of Not Compliance With Agreement LineOfCreditFacilityMaximumBorrowingCapacityInCaseOfNotComplianceWithAgreement	750000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41156	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34965	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	63155	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	76484	USD
CY2013Q1	us-gaap	Inventory Write Down InventoryWriteDown	25699	USD
CY2014Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33631	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	139744	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-14162	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	102659	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-56378	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-60186	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-31491	USD
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.00
CY2014Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.095
CY2013Q4	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2600000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	135090	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	265733	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	72133	USD
CY2013Q1	nuro	Increase Decrease In Deferred Revenue Deferred Costs And Other Liabilities IncreaseDecreaseInDeferredRevenueDeferredCostsAndOtherLiabilities	-16950	USD
CY2014Q1	nuro	Increase Decrease In Deferred Revenue Deferred Costs And Other Liabilities IncreaseDecreaseInDeferredRevenueDeferredCostsAndOtherLiabilities	-5356	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1801942	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1608100	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6064	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4115	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6064	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4115	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5281	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5281	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1813287	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1612215	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8699478	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6886191	USD
CY2013Q1	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	-285296	USD
CY2014Q1	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	0	USD
CY2013Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4500000	USD
CY2013Q2	nuro	Class Of Warrant Or Right Exercisable Period ClassOfWarrantOrRightExercisablePeriod	P5Y
CY2013Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	248147	shares
CY2013Q2	us-gaap	Share Price SharePrice	2.095
CY2014Q1	nuro	Preferred Stock Stated Value Per Share PreferredStockStatedValuePerShare	1000
CY2013Q2	nuro	Gross Proceeds From Issuance Or Sale Of Equity GrossProceedsFromIssuanceOrSaleOfEquity	5000000	USD
CY2014Q1	us-gaap	Preferred Stock Discount On Shares PreferredStockDiscountOnShares	766900	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2365934	shares
CY2013Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2365934	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2.00
CY2014Q1	nuro	Entity Date Of Incorporation EntityDateOfIncorporation	1996-06
CY2014Q1	nuro	Common Stock Warrants Remaining Liability CommonStockWarrantsRemainingLiability	1057323	shares
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Trading Symbol TradingSymbol	NURO
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5945581	shares
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	NeuroMetrix, Inc.
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001289850
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	119370	shares
CY2013Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	285300	USD
CY2013Q1	nuro	Closing Price Of Shares ClosingPriceOfShares	2.39
CY2013	us-gaap	Dividends Dividends	0	USD
CY2014Q1	us-gaap	Dividends Dividends	0	USD
CY2013Q4	nuro	Warrants Or Rights Exercised WarrantsOrRightsExercised	1300000	shares

Files In Submission

Name	View Source	Status
0001144204-14-024572-index-headers.html	Edgar Link	pending
0001144204-14-024572-index.html	Edgar Link	pending
0001144204-14-024572.txt	Edgar Link	pending
0001144204-14-024572-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nuro-20140331.xml	Edgar Link	completed
nuro-20140331.xsd	Edgar Link	pending
nuro-20140331_cal.xml	Edgar Link	unprocessable
nuro-20140331_def.xml	Edgar Link	unprocessable
nuro-20140331_lab.xml	Edgar Link	unprocessable
nuro-20140331_pre.xml	Edgar Link	unprocessable
page1.jpg	Edgar Link	pending
page2.jpg	Edgar Link	pending
page3.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v374547_10q.htm	Edgar Link	pending
v374547_ex10-1.htm	Edgar Link	pending
v374547_ex31-1.htm	Edgar Link	pending
v374547_ex31-2.htm	Edgar Link	pending
v374547_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NURO
NeuroMetrix, Inc. Stock $nuro

2014 Q2 Form 10-Q Financial Statement

#000114420414024572 Filed on April 24, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO NeuroMetrix, Inc. Stock $nuro

2014 Q2 Form 10-Q Financial Statement

#000114420414024572 Filed on April 24, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO
NeuroMetrix, Inc. Stock $nuro